135 related articles for article (PubMed ID: 21689208)
1. Does it ever make sense to treat a bacterial infection with a drug against which the responsible pathogen possesses a resistance mechanism?
Tassios PT; Miriagou V
Clin Microbiol Infect; 2011 Aug; 17(8):1126-7. PubMed ID: 21689208
[No Abstract] [Full Text] [Related]
2. A silver bullet for colonization and infection with methicillin-resistant Staphylococcus aureus still eludes us.
Rice LB
Clin Infect Dis; 1999 May; 28(5):1067-70. PubMed ID: 10452636
[No Abstract] [Full Text] [Related]
3. First outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Constantine, Algeria.
Cuzon G; Bentchouala C; Vogel A; Héry M; Lezzar A; Smati F; Dortet L; Naas T
Int J Antimicrob Agents; 2015 Dec; 46(6):725-7. PubMed ID: 26453148
[No Abstract] [Full Text] [Related]
4. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?
Daikos GL; Markogiannakis A
Clin Microbiol Infect; 2011 Aug; 17(8):1135-41. PubMed ID: 21635663
[TBL] [Abstract][Full Text] [Related]
5. Successful containment and infection control of a Carbapenem-resistant Klebsiella pneumoniae outbreak in an Italian hospital.
Gaibani P; Colombo R; Arghittu M; Cariani L; Ambretti S; Bua G; Lombardo D; Landini MP; Torresani E; Sambri V
New Microbiol; 2014 Jan; 37(1):87-90. PubMed ID: 24531175
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
7. First detection of oxacillinase-mediated resistance to carbapenems in Klebsiella pneumoniae from Morocco.
Benouda A; Touzani O; Khairallah MT; Araj GF; Matar GM
Ann Trop Med Parasitol; 2010 Jun; 104(4):327-30. PubMed ID: 20659393
[TBL] [Abstract][Full Text] [Related]
8. A case of New Delhi metallo-β-lactamase 1 (NDM-1)-producing Klebsiella pneumoniae with putative secondary transmission from the Balkan region in the Netherlands.
Halaby T; Reuland AE; Al Naiemi N; Potron A; Savelkoul PH; Vandenbroucke-Grauls CM; Nordmann P
Antimicrob Agents Chemother; 2012 May; 56(5):2790-1. PubMed ID: 22330915
[No Abstract] [Full Text] [Related]
9. Comparative in vitro killing of carbapenems and aztreonam against Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.
Panagiotakopoulou A; Daikos GL; Miriagou V; Loli A; Tzelepi E; Tzouvelekis LS
Int J Antimicrob Agents; 2007 Mar; 29(3):360-2. PubMed ID: 17223016
[No Abstract] [Full Text] [Related]
10. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients.
Coskun K
Liver Transpl; 2016 Jan; 22(1):130. PubMed ID: 26335447
[No Abstract] [Full Text] [Related]
11. Piscidin is highly active against carbapenem-resistant Acinetobacter baumannii and NDM-1-producing Klebsiella pneumonia in a systemic Septicaemia infection mouse model.
Pan CY; Chen JC; Chen TL; Wu JL; Hui CF; Chen JY
Mar Drugs; 2015 Apr; 13(4):2287-305. PubMed ID: 25874924
[TBL] [Abstract][Full Text] [Related]
12. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae.
Meletis G; Tzampaz E; Sianou E; Tzavaras I; Sofianou D
J Antimicrob Chemother; 2011 Apr; 66(4):946-7. PubMed ID: 21393203
[No Abstract] [Full Text] [Related]
13. Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.
Camargo JF; Simkins J; Beduschi T; Tekin A; Aragon L; Pérez-Cardona A; Prado CE; Morris MI; Abbo LM; Cantón R
Antimicrob Agents Chemother; 2015 Oct; 59(10):5903-8. PubMed ID: 26386029
[TBL] [Abstract][Full Text] [Related]
14. Emergence of carbapenem resistance due to porin loss in an extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy.
Webster DP; Gaulton T; Woodford N; Pike R; Turton J; Perry C; Bowler IC
Int J Antimicrob Agents; 2010 Dec; 36(6):575-6. PubMed ID: 20869852
[No Abstract] [Full Text] [Related]
15. Carbapenemase-producing Klebsiella pneumoniae: a major clinical challenge.
Mandrawa CL; Cronin K; Buising KL; Poy Lorenzo YS; Waters MJ; Jeremiah CJ
Med J Aust; 2016 Apr; 204(7):277-8. PubMed ID: 27078606
[No Abstract] [Full Text] [Related]
16. Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections: a critical agenda.
De Rosa FG; Corcione S; Cavallo R; Di Perri G; Bassetti M
Future Microbiol; 2015; 10(2):283-94. PubMed ID: 25689539
[TBL] [Abstract][Full Text] [Related]
17. Klebsiellapneumoniae isolates possessing KPC beta-lactamase in Israel, Puerto Rico, Colombia and Greece.
Hawser SP; Bouchillon SK; Hoban DJ; Hackel M; Johnson JL; Badal RE
Int J Antimicrob Agents; 2009 Oct; 34(4):384-5. PubMed ID: 19560904
[No Abstract] [Full Text] [Related]
18. ST147 NDM-1-producing Klebsiella pneumoniae spread in two Tunisian hospitals.
Messaoudi A; Haenni M; Mansour W; Saras E; Bel Haj Khalifa A; Chaouch C; Naija W; Boujâafar N; Bouallègue O; Madec JY
J Antimicrob Chemother; 2017 Jan; 72(1):315-316. PubMed ID: 27659734
[No Abstract] [Full Text] [Related]
19. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary.
Landman D; Chockalingam M; Quale JM
Clin Infect Dis; 1999 May; 28(5):1062-6. PubMed ID: 10452635
[TBL] [Abstract][Full Text] [Related]
20. [Klebsiella infection].
Nakahama C
Nihon Rinsho; 2003 Feb; 61 Suppl 2():378-82. PubMed ID: 12722247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
